2010 年乳腺癌的免疫疗法：炒作还是希望？
Immune therapy for breast cancer in 2010-hype or hope?
机构信息
Division of Medical Oncology and Hematology, Princess Margaret Hospital, and Department of Medicine, University of Toronto, Toronto, ON.
出版信息
Curr Oncol. 2011 Jan;18(1):e9-e18. doi: 10.3747/co.v18i1.623.
Abstract
The identification of numerous breast cancer antigens has generated increasing enthusiasm for the application of immune-based therapies in breast malignancies. Although the use of monoclonal antibodies has revolutionized the "targeted therapy" of breast cancer, and the immunomodulatory effects of bisphosphonates continue to be evaluated, few studies to date have demonstrated widespread utility for other forms of immunotherapy. The present review assesses modern research and explores whether the hopes for immunotherapy can overcome the hype.
摘要
已经鉴定出许多乳腺癌抗原，这使得人们对免疫疗法在乳腺癌中的应用产生了浓厚的兴趣。尽管单克隆抗体的应用已经彻底改变了乳腺癌的“靶向治疗”，并且双磷酸盐的免疫调节作用仍在不断评估中，但迄今为止，很少有研究表明其他形式的免疫疗法具有广泛的应用价值。本文综述了现代研究，并探讨了免疫疗法的希望是否能够克服炒作。
相似文献
1
Immune therapy for breast cancer in 2010-hype or hope?2010 年乳腺癌的免疫疗法：炒作还是希望？
Curr Oncol. 2011 Jan;18(1):e9-e18. doi: 10.3747/co.v18i1.623.
2
Immunotherapeutic approaches for the treatment of breast cancer.用于治疗乳腺癌的免疫治疗方法。
J Mammary Gland Biol Neoplasia. 1999 Oct;4(4):353-65. doi: 10.1023/a:1018714300217.
3
An efficient or methodical review of immunotherapy against breast cancer.针对乳腺癌的免疫疗法的高效或系统回顾。
J Biochem Mol Toxicol. 2019 Aug;33(8):e22339. doi: 10.1002/jbt.22339. Epub 2019 Jun 3.
4
5
From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?从患者权益倡导者的角度来看：癌症免疫疗法是否代表了一种范式转变？
Curr Oncol Rep. 2018 Feb 7;20(1):8. doi: 10.1007/s11912-018-0662-5.
6
Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines.乳腺癌免疫疗法：现代检查点阻断策略与疫苗概述
Curr Probl Cancer. 2016 Mar-Aug;40(2-4):151-162. doi: 10.1016/j.currproblcancer.2016.09.009. Epub 2016 Sep 26.
7
Progress in Vaccine Therapies for Breast Cancer.疫苗疗法在乳腺癌治疗中的进展。
Adv Exp Med Biol. 2017;1026:315-330. doi: 10.1007/978-981-10-6020-5_15.
8
Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.乳腺癌免疫疗法：单克隆抗体与基于肽的疫苗。
Expert Rev Clin Immunol. 2014 Jul;10(7):927-61. doi: 10.1586/1744666X.2014.916211. Epub 2014 May 28.
9
Next generation of immunotherapy for melanoma.黑色素瘤的下一代免疫疗法。
J Clin Oncol. 2008 Jul 10;26(20):3445-55. doi: 10.1200/JCO.2007.14.6423.
10
Immune Checkpoint Blockade in Breast Cancer Therapy.免疫检查点阻断在乳腺癌治疗中的应用。
Adv Exp Med Biol. 2017;1026:383-402. doi: 10.1007/978-981-10-6020-5_18.
引用本文的文献
1
Advances in nanotechnology-enabled adjuvants for peptide-based cancer vaccines.基于肽的癌症疫苗的纳米技术辅助剂研究进展。
Nano Res. 2025 Jul;18(7). doi: 10.26599/nr.2025.94907534. Epub 2025 May 22.
2
Bridging molecular insights and clinical application: non-coding RNAs, targeted drug delivery, and metastatic breast cancer therapy.架起分子见解与临床应用之间的桥梁：非编码RNA、靶向药物递送与转移性乳腺癌治疗
Discov Oncol. 2025 Jul 26;16(1):1413. doi: 10.1007/s12672-025-03090-1.
3
Breast Cancer: Targeting of Steroid Hormones in Cancerogenesis and Diagnostics.乳腺癌：甾体激素在癌症发生和诊断中的靶向作用。
Int J Mol Sci. 2021 May 30;22(11):5878. doi: 10.3390/ijms22115878.
4
Evaluation of Breast Cancer (BC) Awareness among Female University Students in Zarqa University, Jordan.约旦扎尔卡大学女大学生对乳腺癌（BC）的认知评估。
Eur J Breast Health. 2018 Oct 1;14(4):199-204. doi: 10.5152/ejbh.2018.4048. eCollection 2018 Oct.
5
Widespread Non-Canonical Epigenetic Modifications in MMTV-NeuT Breast Cancer.MMTV-NeuT乳腺癌中广泛存在的非经典表观遗传修饰
Neoplasia. 2015 Apr;17(4):348-57. doi: 10.1016/j.neo.2015.02.006.
6
Prevalence of BRCA1 gene mutation in breast cancer patients in Guangxi, China.中国广西乳腺癌患者中BRCA1基因突变的患病率
Int J Clin Exp Pathol. 2014 Aug 15;7(9):6262-9. eCollection 2014.
7
Dracorhodin perchlorate induced human breast cancer MCF-7 apoptosis through mitochondrial pathways.高氯酸血根碱通过线粒体途径诱导人乳腺癌 MCF-7 细胞凋亡。
Int J Med Sci. 2013 Jul 7;10(9):1149-56. doi: 10.7150/ijms.6275. Print 2013.
8
T cell coinhibition and immunotherapy in human breast cancer.人类乳腺癌中的T细胞共抑制与免疫治疗
Discov Med. 2012 Oct;14(77):229-36.
9
Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study.中国女性乳腺癌分子亚型的独特分布及其预后意义：一项基于人群的队列研究。
BMC Cancer. 2011 Jul 12;11:292. doi: 10.1186/1471-2407-11-292.
本文引用的文献
1
An autoimmune-mediated strategy for prophylactic breast cancer vaccination.一种用于预防性乳腺癌疫苗接种的自身免疫介导策略。
Nat Med. 2010 Jul;16(7):799-803. doi: 10.1038/nm.2161. Epub 2010 May 30.
2
A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu.一项针对 HER-2/neu 表达的难治性转移性肿瘤患者使用 lapuleucel-T（APC8024）进行免疫治疗的 I 期临床试验。
Clin Cancer Res. 2009 Sep 15;15(18):5937-44. doi: 10.1158/1078-0432.CCR-08-3282. Epub 2009 Sep 1.
3
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.一项针对既往使用曲妥珠单抗治疗失败的转移性乳腺癌（MBC）患者，开展曲妥珠单抗联合低剂量白细胞介素-2（IL-2）的II期试验。
Breast Cancer Res Treat. 2009 Sep;117(1):83-9. doi: 10.1007/s10549-008-0251-7. Epub 2008 Dec 3.
4
Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.HER2/neu（E75）疫苗预防高危乳腺癌患者复发的联合临床试验结果：美国军事癌症研究所临床试验组研究I - 01和I - 02。
Clin Cancer Res. 2008 Feb 1;14(3):797-803. doi: 10.1158/1078-0432.CCR-07-1448.
5
Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.用基于HER-2的抗原Lapuleucel-T激活的自体抗原呈递细胞进行治疗：HER-2过表达乳腺癌免疫和临床活性的I期研究结果
J Clin Oncol. 2007 Aug 20;25(24):3680-7. doi: 10.1200/JCO.2006.10.5718.
6
Development of vaccines for high-risk ductal carcinoma in situ of the breast.针对乳腺高危导管原位癌的疫苗研发。
Cancer Res. 2007 Jul 15;67(14):6531-4. doi: 10.1158/0008-5472.CAN-07-0878.
7
Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.化疗和唑来膦酸使实体瘤细胞对Vγ9Vδ2 T细胞的细胞毒性敏感。
Cancer Immunol Immunother. 2007 Aug;56(8):1285-97. doi: 10.1007/s00262-007-0279-2. Epub 2007 Jan 31.
8
Immunotherapy for renal cell cancer.肾细胞癌的免疫疗法。
J Clin Oncol. 2006 Dec 10;24(35):5576-83. doi: 10.1200/JCO.2006.08.3774.
9
Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy.免疫调节寡核苷酸作为乳腺癌的新型疗法：药代动力学、体外和体内抗癌活性以及抗体疗法的增强作用。
Mol Cancer Ther. 2006 Aug;5(8):2106-14. doi: 10.1158/1535-7163.MCT-06-0158.
10
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.曲妥珠单抗、紫杉醇和卡铂与曲妥珠单抗和紫杉醇对比治疗HER-2过表达转移性乳腺癌女性患者的随机III期研究。
J Clin Oncol. 2006 Jun 20;24(18):2786-92. doi: 10.1200/JCO.2005.04.1764.
Zotero 插件